The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease

BACKGROUND: Rituximab is a B cell depleting anti-CD20 monoclonal antibody. CD20 is not expressed on mature plasma cells and accordingly rituximab does not have immediate effects on immunoglobulin levels. However, after rituximab some patients develop hypogammaglobulinaemia. METHODS: We performed a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Marco, Helena, Smith, Rona M, Jones, Rachel B, Guerry, Mary-Jane, Catapano, Fausta, Burns, Stella, Chaudhry, Afzal N, Smith, Kenneth GC, Jayne, David RW
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038057/
https://www.ncbi.nlm.nih.gov/pubmed/24884562
http://dx.doi.org/10.1186/1471-2474-15-178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038057/
https://www.ncbi.nlm.nih.gov/pubmed/24884562
http://dx.doi.org/10.1186/1471-2474-15-178

Ejemplares similares